BIO-PATH HOLDINGS INC. news, videos and press releases
For more news please use our advanced search feature.
BIO-PATH HOLDINGS INC. - More news...
BIO-PATH HOLDINGS INC. - More news...
- Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
- Bio-Path Holdings Expands Global Patent Portfolio
- Bio-Path Holdings Provides 2024 Clinical and Operational Update
- Bio-Path Holdings Reports Full Year 2023 Financial Results
- Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
- Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
- Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
- Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
- Bio-Path Holdings Reports Third Quarter 2023 Financial Results
- Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
- Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
- Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Bio-Path Holdings Reports Second Quarter 2023 Financial Results
- Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
- Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
- Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
- Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
- Bio-Path Holdings Reports First Quarter 2023 Financial Results
- Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
- Bio-Path Holdings Reports Full Year 2022 Financial Results
- Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
- Bio-Path Holdings Provides Clinical and Operational Update
- Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
- Bio-Path Holdings Reports Third Quarter 2022 Financial Results
- Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
- Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement
- Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
- Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference